Filing Details
- Accession Number:
- 0001127602-20-031532
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-16 16:15:36
- Reporting Period:
- 2020-12-14
- Accepted Time:
- 2020-12-16 16:15:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1682852 | Moderna Inc. | MRNA | Biological Products, (No Disgnostic Substances) (2836) | 813467528 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1690927 | Zvi Tal Zaks | C/O Moderna, Inc. 200 Technology Square Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-12-14 | 10,000 | $20.93 | 10,000 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-12-14 | 34 | $14.22 | 10,034 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-12-14 | 5,000 | $12.21 | 15,034 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2020-12-14 | 10,000 | $19.15 | 25,034 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-12-14 | 1,402 | $154.25 | 23,632 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 3,733 | $155.16 | 19,899 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 4,922 | $156.27 | 14,977 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 5,509 | $157.17 | 9,468 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 1,000 | $158.35 | 8,468 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 2,358 | $159.73 | 6,110 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 2,907 | $160.58 | 3,203 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 2,502 | $161.65 | 701 | No | 4 | S | Direct | |
Common Stock | Disposition | 2020-12-14 | 701 | $162.63 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-14 | 10,000 | $0.00 | 10,000 | $20.93 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-14 | 34 | $0.00 | 34 | $14.22 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-14 | 5,000 | $0.00 | 5,000 | $12.21 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-12-14 | 10,000 | $0.00 | 10,000 | $19.15 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
201,998 | 2020-03-08 | 2029-03-08 | No | 4 | M | Direct |
50,175 | 2028-02-28 | No | 4 | M | Direct | |
197,291 | 2027-10-03 | No | 4 | M | Direct | |
4,790 | 2026-08-10 | No | 4 | M | Direct |
Footnotes
- The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $153.67 to $154.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $154.68 to $155.65. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.73 to $156.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.77 to $157.69. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.10 to $158.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.14 to $160.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.17 to $161.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.34 to $162.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.48 to $162.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- 25% of this option vested and became exercisable on February 27, 2019 with the remainder vesting in 12 equal quarterly installments thereafter.
- 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
- This option is fully vested and exercisable.